<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02977507</url>
  </required_header>
  <id_info>
    <org_study_id>SKM16-LYT-MEL</org_study_id>
    <nct_id>NCT02977507</nct_id>
  </id_info>
  <brief_title>Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Subjects With Moderate Facial Melasma</brief_title>
  <official_title>Randomized, Double-blinded, Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Subjects With Moderate Facial Melasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus
      4% hydroquinone in the improvement of the appearance of moderate facial melasma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Actual">October 9, 2017</completion_date>
  <primary_completion_date type="Actual">October 9, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator assessment of symmetrical facial melasma using the Melasma Severity Rating Scale on the left facial side</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Hyperpigmentation Status will be assessed based on a 0 to 3 scale. 0=Cleared, 1=Mild, 2=Moderate, 3=Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator assessment of symmetrical facial melasma using the Melasma Severity Rating Scale on the right facial side</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Hyperpigmentation Status will be assessed based on a 0 to 3 scale. 0=Cleared, 1=Mild, 2=Moderate, 3=Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator assessment of subject's left facial side for Overall Hyperpigmentation</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Overall hyperpigmentation will be assessed based on a 0-9 scale. 0=None, 1-3=Mild, 4-6=Moderate, 7-9=Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator assessment of subject's right facial side for Overall Hyperpigmentation</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Overall hyperpigmentation will be assessed based on a 0-9 scale. 0=None, 1-3=Mild, 4-6=Moderate, 7-9=Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Melasma Area Severity Index (MASI) Score for the left facial side</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Score calculated by assessing the total area involved, darkness of pigment and homogeneity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Melasma Area Severity Index (MASI) Score for the right facial side</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Score calculated by assessing the total area involved, darkness of pigment and homogeneity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject's Self-Assessment Questionnaire of the left facial side</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Subject's self-assessment of facial skin quality during and after treatment and the evaluation of self-perceived cosmetic efficacy of the treatment and the product attributes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Self-Assessment Questionnaire of the right facial side</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Subject's self-assessment of facial skin quality during and after treatment and the evaluation of self-perceived cosmetic efficacy of the treatment and the product attribute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject MELASQOL Assessment of the left facial side</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>On a Likert scale of 1 (not bothered at all) to 7 (bothered all the time), the subject rates how he or she feels about:
1=The appearance of your skin condition, 2=Frustration about your skin condition, 3=Embarrassment about your skin condition, 4=Feeling depressed about your skin condition, 5=The effects of your skin condition on your interactions with other people (e.g. interactions with family, friends, close relationship, etc.) 6=The effects of your skin condition on your desire to be with people, 7=Your skin condition making it hard to show affection, 8=Skin discoloration making you feel unattractive to others, 9=Skin discoloration making you feel less vital or productive, 10=Skin discoloration affecting your sense of freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject MELASQOL Assessment of the right facial side</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>On a Likert scale of 1 (not bothered at all) to 7 (bothered all the time), the subject rates how he or she feels about:
1=The appearance of your skin condition, 2=Frustration about your skin condition, 3=Embarrassment about your skin condition, 4=Feeling depressed about your skin condition, 5=The effects of your skin condition on your interactions with other people (e.g. interactions with family, friends, close relationship, etc.) 6=The effects of your skin condition on your desire to be with people, 7=Your skin condition making it hard to show affection, 8=Skin discoloration making you feel unattractive to others, 9=Skin discoloration making you feel less vital or productive, 10=Skin discoloration affecting your sense of freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Improvement Assessment for Overall Hyperpigmentation on the left facial side</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Overall hyperpigmentation will be assessed based on a 0-4 scale. 0=No change of worsening, 1=Mild improvement, 2=Moderate improvement, 3=Marked improvement, 4=Complete clearing/Dramatic improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Improvement Assessment for Overall Hyperpigmentation on the right facial side</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Overall hyperpigmentation will be assessed based on a 0-4 scale. 0=No change of worsening, 1=Mild improvement, 2=Moderate improvement, 3=Marked improvement, 4=Complete clearing/Dramatic improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mexameter measurement of target hyperpigmentation lesion from left malar area</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The values from the target hyperpigmented lesions will be compared to the normal lesion value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mexameter measurement of target hyperpigmentation lesion from right malar area</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The values from the target hyperpigmented lesions will be compared to the normal lesion value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Lytera 2.0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lytera 2.0 applied to the affected areas (dark patches) on one side of the face while 4% hydroquinone topical prescription cream applied to the affected areas on the other side. The test products will be applied twice a day, morning and evening, everyday for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4% Hydroquinone Topical Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on one side of the face while Lytera 2.0 applied to the affected areas on the other side. The test products will be applied twice a day, morning and evening, everyday for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lytera 2.0</intervention_name>
    <description>Lytera 2.0 applied to the affected areas twice a day, morning and evening, everyday for 12 weeks.</description>
    <arm_group_label>Lytera 2.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4% Hydroquinone Topical Cream</intervention_name>
    <description>4% Hydroquinone Topical Cream applied to the affected areas twice a day, morning and evening, everyday for 12 weeks.</description>
    <arm_group_label>4% Hydroquinone Topical Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male aged 18+ years with general good health

          -  Individuals with dark patches on both sides of their face

          -  Individuals that are willing to provide written informed consent and are able to read,
             speak, write, and understand English.

          -  Individuals willing to sign have their photographs taken during the study and are
             willing to sign a photography release.

          -  Willing to stop all facial treatments during the course of the study including
             botulinum toxin, injectable fillers, microdermabrasion, IPL, peels, facials, waxing,
             laser treatments and tightening treatments. Threading is allowed but not facial laser
             hair removal.

          -  Willingness to cooperate follow all study requirements for the duration of the study
             and to report any changes in health status or medications, adverse event symptoms, or
             reactions immediately.

          -  Willingness to not begin using any new cosmetic facial make-up during the study. If
             you regularly use cosmetic facial make-up, you must have used the product(s) without
             any issues for at least 2 weeks prior to starting the study.

          -  Willingness to avoid sun exposure to the face as much as possible, (including tanning
             beds), especially from 10 AM to 2 PM. Protective clothing (i.e. hats) and the provided
             sunscreen should be worn prior to and during any exposure.

        Exclusion Criteria:

          -  Individuals diagnosed with known allergies to study provided skin care products.

          -  Individuals who are nursing, pregnant, or planning to become pregnant during the study
             according to subject self-report.

          -  Individuals with a history of skin cancer.

          -  Individuals having a health condition on the face (e.g., psoriasis, rosacea, acne,
             eczema, seborrheic dermatitis, severe excoriations etc.).

          -  Individuals with a history of immunosuppression/immune deficiency disorders (including
             (HIV infection or AIDS) or currently using immunosuppressive medications (e.g.,
             azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate
             mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation.

          -  Individuals with an uncontrolled disease such as asthma, diabetes, hypertension,
             hyperthyroidism, or hypothyroidism. Individuals having multiple health conditions may
             be excluded from participation even if the conditions are controlled by diet,
             medication, etc.

          -  Individuals with any planned surgeries and/or invasive medical procedures during the
             course of the study.

          -  Individuals who are currently participating in any other facial usage study or have
             participated in any clinical trial within 4 weeks prior to inclusion into the study.

          -  Individuals who have observable suntan, scars, nevi, excessive hair, etc. or other
             dermal conditions on the face that might influence the test results in the opinion of
             the Investigator or designee.

          -  Individuals who started hormone replacement therapies (HRT) or hormones for birth
             control less than 3 months prior to study entry or who plan on starting, stopping, or
             changing doses of HRT or hormones for birth control during the study.

          -  Individuals who used any of the following medications or had any of the listed
             procedures within the listed time frame prior to the study start date:

               -  Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, or Differin® within 3 months

               -  Had a light-depth chemical peel or microdermabrasion within 1 month

               -  Had a medium-depth chemical peel, medium-depth microdermabrasion, any systemic
                  steroids, non-ablative laser, light and/or radio frequency or fractional laser
                  resurfacing of the face and neck within 3 months

               -  Any systemic retinoid (e.g. Soriatane®, Accutane®, Roche Dermatologics) within 12
                  months

               -  Any topical or systemic antibiotics, such as minocycline, or any other known
                  medications that can cause photosensitivity, such as hydrochlorothiazide, lasix,
                  amiodarone, within 1 month

               -  Any topical tretinoin product or derivative, imiquimod, 5-fluorouracil, or
                  diclofenac on their face within 3 months

               -  Prescription strength skin lightening products (e.g. 4% hydroquinone, tretinoin,
                  AHA, BHA and polyhydroxy acids, 15% or 20% azelaic acid, 4-hydroxyanisole alone
                  or in combination with tretinoin, etc.) within 3 months

               -  Any non-prescription cosmetic anti-wrinkle, skin lightening products, or any
                  other product or topical or systemic medication known to affect skin aging or
                  dyshcromia (products containing alpha/beta/poly-hydroxy acids, vitamin C, soy,
                  Q-10, hydroquinone; systemic or licorice extract (topically), Tego® Cosmo C250,
                  gigawhite, lemon juice extract (topically), emblica extract, etc.) within 2 weeks

               -  Have undergone plastic surgery, Dermabrasion (deep skin peel), a deep chemical
                  peel or ablative laser resurfacing of the face and neck within 12 months

               -  Had facial treatment with a botulinum toxin base injectable (Botox), injectable
                  fillers, or a fat transfer within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Makino</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai St. Luke's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

